Stock listing

NASDAQ:AGMB AgomAb Therapeutics NV Stock

Follow AgomAb Therapeutics NV into a list and get an email when it puts out news.

Share price · NASDAQ:AGMB

$5.45 USD -0.37 (-6.4%)

Close on Nov 20, 2026

Since Feb 5, 2026 -65.9% · daily closes, Feb 5, 2026 – Nov 20, 2026, adjusted for splits
Day range
$5.39 – $5.78 USDNov 20, 2026
Volume
188,938 sharesNov 20, 2026
Market cap
$268.4M USDAt the close on Nov 20, 2026 · price × 49.25M shares outstanding
Traded on an average day
$1.91M USDMedian day 129,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AgomAb Therapeutics NV logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AGMB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.45-0.37-6.4%$5.51$5.78$5.39188,938
$5.82-0.10-1.7%$6.00$6.25$5.70131,857
$5.92-0.05-0.8%$6.00$6.435$5.50296,439
$5.97-0.39-6.1%$6.36$6.505$5.90165,616
$6.360.000.0%$6.32$6.605$5.731192,639
$6.36-0.63-9.0%$6.90$6.98$6.191,517,921
$6.990.000.0%$7.07$7.23$6.85433,254
$6.99-0.56-7.4%$7.54$7.75$6.80447,059
$7.55-0.085-1.1%$7.72$8.245$7.32661,382
$7.635+0.665+9.5%$7.09$8.15$7.005158,411
$6.97+0.12+1.8%$6.85$7.46$6.47780,328
$6.850.000.0%$7.00$7.085$6.7679,984
$6.85+0.13+1.9%$6.67$7.155$6.6740,243
$6.72-0.77-10.3%$7.57$8.111$6.548105,630
$7.49-0.46-5.8%$7.00$7.955$6.61197,833
$7.95-0.01-0.1%$7.98$8.292$7.47575,393
$7.96-0.44-5.2%$8.37$8.37$7.71105,583
$8.40-0.17-2.0%$8.60$8.60$7.8889,797
$8.57-0.48-5.3%$9.10$9.33$8.4473,647
$9.05-0.21-2.3%$9.15$9.184$8.67549,125
$9.26+0.15+1.6%$9.15$9.44$8.9084,322
$9.11+0.38+4.4%$8.74$9.22$8.7442,422
$8.73+0.50+6.1%$8.24$8.97$8.2335,303
$8.23-0.05-0.6%$8.28$8.61$8.1631,092
$8.28-0.05-0.6%$8.21$8.53$7.9278,133
$8.33-0.36-4.1%$8.56$8.86$8.1597,715
$8.69-0.12-1.4%$8.80$9.08$8.5157,697
$8.81-0.28-3.1%$9.05$9.35$8.7359,400
$9.09+0.01+0.1%$9.18$9.65$9.0562,300
$9.08-0.14-1.5%$9.36$9.49$8.92102,100
$9.22+0.42+4.8%$8.88$9.45$8.56225,200
$8.80-0.04-0.5%$8.95$9.35$8.68104,900
$8.84+0.15+1.7%$8.77$8.97$8.40103,900
$8.69+0.13+1.5%$8.51$8.71$7.97129,600
$8.56-0.09-1.0%$8.65$9.34$8.00388,700
$8.65-2.45-22.1%$11.21$11.32$8.56639,200
$11.10+0.57+5.4%$10.62$11.36$10.58133,700
$10.53+0.32+3.1%$10.23$10.69$10.14113,500
$10.21-0.30-2.9%$10.51$10.54$9.87147,200
$10.51-0.07-0.7%$10.65$11.23$10.41164,000
$10.58-0.19-1.8%$10.75$10.99$10.5064,200
$10.77-0.72-6.3%$11.54$11.80$10.6498,700
$11.49-0.21-1.8%$11.70$11.85$11.3149,400
$11.70-0.47-3.9%$12.26$12.26$11.2885,400
$12.17+0.09+0.7%$12.26$12.99$11.60250,700
$12.08+0.67+5.9%$11.66$12.46$11.62339,300
$11.41-0.75-6.2%$12.26$12.85$11.21120,300
$12.16-0.12-1.0%$12.31$12.92$11.61146,300
$12.28-0.78-6.0%$13.20$13.29$12.2086,200
$13.06-0.88-6.3%$14.00$14.10$12.96196,700
$13.94-1.02-6.8%$14.91$16.40$13.75106,700
$14.96+0.05+0.3%$14.94$15.70$14.6572,600
$14.91-0.87-5.5%$15.78$16.50$14.51260,600
$15.78+0.95+6.4%$14.83$15.86$14.53245,300
$14.83+1.17+8.6%$13.67$14.94$13.59407,900
$13.66+0.12+0.9%$13.29$13.96$13.19158,900
$13.54+0.37+2.8%$12.90$13.99$12.62241,300
$13.170.000.0%$13.15$14.13$12.75105,400
$13.17-0.67-4.8%$13.84$14.20$12.84252,900
$13.84-0.44-3.1%$14.26$14.37$13.66154,200
$14.28+0.26+1.9%$14.19$14.60$13.58243,700
$14.02+1.20+9.4%$13.40$14.26$13.16219,354
$12.82-0.43-3.2%$13.21$13.23$12.7631,651
$13.25-0.18-1.3%$13.50$13.64$13.0768,400
$13.43-0.32-2.3%$13.74$13.85$13.0192,200
Ticker
NASDAQ:AGMB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All AgomAb Therapeutics NV news

AgomAb Therapeutics NV on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 16 in all · newest Nov 4, 2026 · oldest 2026
Decks
2 decks · latest Oct 1, 2026

Valuation

Price/book 0.9× against a median of 2.1×: 2nd lowest of 8 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$6.88M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.29

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AgomAb Therapeutics NV · NASDAQ:AGMBUS$268.4M−US$6.88Mn/an/an/a0.9×n/a0.0×1.29
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.1MUS$182.5Mn/a467×n/a3.3×n/a0.0×n/a
Agenus Inc. · NASDAQ:AGENUS$270.1MUS$218.3M9.2×1.6×4.0×n/a22.0%n/a1.80
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.5MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
Median of the othersUS$262.6MUS$175.3M9.2×37.3×4.0×2.1×−112.6%0.1×1.48

Forecasts

4 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
37.67 USD · Analysts' mean
EPS, year to Dec 2026
-1.81 · 6 analysts

Team and board

Officers

OfficerRole
Tim KnotnerusChief Executive Officer
Pierre KemulaChief Financial Officer
Ellen LefeverGeneral Counsel
Sofie Van GijselVP of Investor Relations
Andrea SáezChief Development Officer
Paul van der HorstChief Business Officer
Philippe WieselChief Medical Officer

Board

DirectorRole
David EpsteinChairman of the Board
Angelika JahreisNon-Executive Director
Colin BondNon-Executive Director and Chairman of the Audit Committee
Felice VerduynRepresenting EQT Life Sciences
Marino GarciaNon-Executive Director
Naimish PatelNon-Executive Director
Ohad HammerRepresenting Pontifax

Events

QuarterResultsShare move
Q1 2026Apr 24, 2026+5.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck29 slidesOct 1, 2026
Investor Presentation (August 2026)Investor deck50 slidesAugust 2026

Open Decks

Financings

RaiseDate
Public offering of american Depositary Shares
Closed: US$200M raised · US$16 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), Leerink Partners (co-lead), Van Lanschot Kempen (co-lead)
Feb 9, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 an ADS on Feb 5, 2026.

Price
US$16.00 an ADS
Offering size
US$200 million
Underwriters' option
Up to 1,875,000 more ADSs
Listing
AGMB on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Morgan Stanley, Leerink Partners, Van Lanschot Kempen · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJun 20, 2024
Filed publiclyJan 16, 2026
Amended onceJan 29, 2026
Declared effective by the SECJan 30, 2026
Shares registered with an exchangeFeb 3, 2026
Final prospectus, with the priceFeb 6, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Feb 6, 2026

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Cost of revenue210.4K
Gross profit-210.4K
Research and development48.9M39.3M26.3M19.4M
Selling, general and administrative12.6M9.82M6.00M4.49M
Operating income-59.3M-48.0M-31.2M-22.6M
Depreciation and amortization219.0K311.0K99.0K23.0K
EBITDA-59.1M-47.7M-31.1M-22.6M
Interest expense60.0K67.0K31.0K45.0K
Income before tax-62.5M-46.3M-12.0M-10.8M
Income tax4.00K4.00K-619.0K-2.66M
Net income-62.5M-46.3M-11.4M-8.14M
Earnings per share, basic-1.28-1.28-0.31-0.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents86.4M171.5M122.4M27.7M53.6M
Short-term investments30.1M0040.0M0
Receivables4.78M
Current assets121.2M173.8M139.5M71.1M54.4M
Goodwill10.1M8.61M8.61M8.61M8.61M
Total assets153.7M206.4M171.3M101.0M84.0M
Accounts payable7.63M5.95M6.83M3.90M1.06M
Current liabilities18.6M9.13M10.9M29.7M33.7M
Long-term debt690.0K
Total debt1.25M
Total liabilities22.8M18.3M19.8M34.7M41.6M
Shareholders' equity130.9M188.1M151.4M66.2M42.4M
Shares outstanding48.7M36.2M36.2M36.2M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-51.7M-46.8M-24.6M-19.0M
Capital spending-4.00K-675.0K00
Free cash flow-51.7M-47.5M-24.6M-19.0M
Cash from investing-33.0M
Cash from financing-338.0K96.8M79.3M37.6M
Change in cash-85.0M49.3M94.7M-25.9M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
4 · Change in ownershipOct 22, 2026Insider tradeSEC
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
All 52 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerOct 1, 2026Current reportSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 15, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 15, 2026Insider tradeSEC
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
6-K · Report of a foreign issuerAug 10, 2026Current reportSEC
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
6-K · Report of a foreign issuerJun 23, 2026Current reportSEC
6-K · Report of a foreign issuerMay 27, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerApr 24, 2026Current reportSEC
20-F · Annual reportApr 23, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeApr 16, 2026Big-stake noticeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 11, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeMar 6, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMar 5, 2026Current reportSEC
SCHEDULE 13D · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
424B4 · ProspectusFeb 6, 2026Offer documentSEC
CERT · Exchange's certificate of listingFeb 5, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 3, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
F-1/A · Registration statement, amendedJan 29, 2026Offer documentSEC
F-1 · Registration statementJan 16, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedDec 17, 2025Offer documentSEC
DRS/A · Draft registration statement, amendedOct 27, 2025Offer documentSEC
DRS · Draft registration statementJun 20, 2024Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from AgomAb Therapeutics NV’s releases · as of Feb 9, 2026

Common shares
49,247,975
Fully diluted
49,247,975

Fully diluted

LineShares
Common shares49,247,975

Share count over time

CountShares
Nov 22, 202649,247,975

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
EQT Fund Management S.a r.l.5.14M10.4%US$57.1MSep 30, 2026
Sanofi2.78M5.7%US$30.9MSep 30, 2026
Cormorant Asset Management, LP2.47M5.0%US$27.4MSep 30, 2026
Pfizer Inc2.15M4.4%US$22.6MSep 30, 2026
TCG Crossover Management, LLC1.82M3.7%US$20.2MSep 30, 2026
Nantahala Capital Management, LLC1.75M3.5%US$19.4MSep 30, 2026
Redmile Group, LLC1.74M3.5%US$19.3MSep 30, 2026
Federated Hermes, Inc.1.61M3.3%US$17.9MSep 30, 2026
Casdin Capital, LLC1.55M3.1%US$17.2MSep 30, 2026
Andera Partners1.54M3.1%US$17.1MSep 30, 2026
All 38 holders
HolderSharesOf the companyValueAs of
Fidelity1.46M3.0%US$16.2MSep 30, 2026
abrdn1.24M2.5%US$13.7MSep 30, 2026
Perceptive Advisors LLC600K1.2%US$6.66MSep 30, 2026
Samsara Biocapital, LLC595K1.2%US$6.6MSep 30, 2026
Siren, L.L.C.411K0.84%US$4.56MSep 30, 2026
Woodline Partners LP251K0.51%US$2.79MSep 30, 2026
Integral Health Asset Management, LLC235K0.48%US$2.61MSep 30, 2026
Seven Grand Managers, LLC200K0.41%US$2.22MSep 30, 2026
Two Sigma91,2430.19%US$1.01MSep 30, 2026
Point72 Asset Management, L.P.67,0320.14%US$744KSep 30, 2026
Alps Advisors Inc64,7780.13%US$719KSep 30, 2026
Jane Street59,2080.12%US$657KSep 30, 2026
Quadrature Capital Ltd54,4240.11%US$604KSep 30, 2026
UBS51,5160.10%US$572KSep 30, 2026
Bellevue Group AG34,8360.07%US$387KSep 30, 2026
Hrt Financial LP31,8810.06%US$353KSep 30, 2026
Walleye Capital LLC23,7170.05%US$263KSep 30, 2026
Crossmark Global Holdings, Inc.23,0960.05%US$256KSep 30, 2026
XTX Topco Ltd19,5830.04%US$217KSep 30, 2026
Citadel11,6350.02%US$129KSep 30, 2026
China Universal Asset Management Co., Ltd.7,2000.01%US$75,816Sep 30, 2026
Morgan Stanley6,1460.01%US$68,221Sep 30, 2026
Osaic Holdings, Inc.398<0.01%US$4,418Sep 30, 2026
Silver Grove Financial Group, Inc.112<0.01%US$1,243Sep 30, 2026
Superior Planning, LLC76<0.01%US$844Sep 30, 2026
Pinnacle Wealth Planning Services, Inc.74<0.01%US$821Sep 30, 2026
Caitong International Asset Management Co., Ltd11<0.01%US$122Sep 30, 2026
SBI Securities Co., Ltd.2<0.01%US$22Sep 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Epstein David R
Director
Buy5,000USD 5.57US$27,850Nov 17, 2026
Epstein David R
Director
Buy5,000USD 5.99US$29,950Nov 13, 2026
Epstein David R
Director
Buy20USD 6.00US$120Nov 13, 2026
Epstein David R
Director
Buy5,000USD 5.75US$28,750Nov 13, 2026
Epstein David R
Director
Buy4,960USD 6.02US$29,859Nov 13, 2026
Epstein David R
Director
Buy5,000USD 6.81US$34,050Nov 5, 2026
Epstein David R
Director
Buy5,000USD 6.91US$34,550Nov 5, 2026
Epstein David R
Director
Buy5,000USD 6.98US$34,900Nov 5, 2026
Epstein David R
Director
Buy5,000USD 8.86US$44,300Oct 21, 2026
Epstein David R
Director
Buy5,000USD 8.90US$44,500Oct 21, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David R. Epstein
Other companies: Tempus AI, Inc. (Director · Since at least Jun 13, 2024); Seagen Inc (CEO, Director · Nov 10, 2023 – Dec 14, 2023 · Past)
Director · Since at least Mar 18, 2026
Marino Garcia
Other companies: Dianthus Therapeutics, Inc. (President & Chief Executive Officer, Board Member · Since at least Sep 11, 2023); Synergy Pharmaceuticals Inc (EVP and Chief Strategy Officer · Jan 5, 2018 – Jan 5, 2018 · Past)
Director · Since at least Sep 11, 2026
Naimish Patel
Other companies: CRISPR Therapeutics AG (Chief Medical Officer · Since at least Jun 1, 2026)
Non-Executive Director · Since at least Sep 11, 2026
Weegen Felice Isabel Verduyn-van
Other companies: Evommune, Inc. (Director · Since at least Nov 5, 2025)
Director · Since at least Mar 18, 2026
Andrea SáezChief Development Officer · Since at least Nov 4, 2026
Andrea Saez BorderiasChief Development Officer · Since at least Mar 18, 2026
Angelika JahreisNon-Executive Director · Since at least Nov 5, 2026
Colin BondDirector · Since at least Mar 18, 2026
ContactsInvestors Sofie Van GijselVP of Investor RelationsE-mail · May 27, 2026 – Nov 5, 2026 · Past
Ellen LefeverGeneral Counsel · Since at least Mar 18, 2026
All 17 people
PersonSeat
Felice VerduynRepresenting EQT Life Sciences · Since at least Nov 5, 2026
Ohad HammerRepresenting Pontifax · Since at least Mar 18, 2026
Paul van der HorstChief Business Officer · Since at least Mar 18, 2026
Philippe WieselChief Medical Officer · Since at least Mar 18, 2026
Pierre KemulaChief Financial Officer · Since at least Mar 18, 2026
Sofie Van GijselVP of Investor Relations · Since at least Nov 4, 2026
Tim KnotnerusChief Executive Officer · Since at least Sep 11, 2026

Open People

Log in to ask 6ix AI your own questions about AgomAb Therapeutics NV.